Skip to main navigation
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
Pharvaris N.V. homepage
  • Disease Focus
  • Community Commitment
  • Scientific Approach
    • Our Science
    • Pipeline
  • Scientific Publications
  • About Pharvaris
  • DEFLATEHAE.COM
  • Investors & News
  • Careers
  • Contact

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

CIIC Spring 2025 Conference

Apr 4 - Apr 6, 2025

  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
    Format: e-Poster

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 1 MB
Pharvaris N.V.

©2026 Pharvaris N.V. © All Rights Reserved

Menu
  • Privacy Policy
  • Clinical Trial Privacy Notice
  • Global Privacy Laws
  • Terms of Use
CONTACT US
FOLLOW US